Melior Discovery in the news

< Back to main News page

Melior Enters Research Collaboration with AstraZeneca

Melior Discovery, Inc. announced today that it has signed an agreement with AstraZeneca PLC
under which Melior’s in-vivo theraTRACE® indications discovery platform will be used to
evaluate the therapeutic activity of selected AstraZeneca compounds.

EXTON, Pa. (Business Wire EON) August 19, 2008 -- "Our agreement represents a significant opportunity for
Melior to deliver value to AstraZeneca through the application of our unique and innovative in vivo testing
platform," said Andrew Reaume, PhD, President and CEO of Melior. "We look forward to a productive
collaboration."

Melior Discovery Overview
Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique theraTRACE® platform of multiplexed in vivo models. The Company is building a pipeline of drug candidates by identifying “privileged” compounds that have been discontinued by other companies and repositioning these molecules in new high potential therapeutic areas. Melior is fortunate to be working exclusively with Dr. Chris Lipinski who assists the Company in identifying ideal repositioning candidates. In addition, Melior offers pharmaceutical and biotechnology companies an opportunity to expand their development pipelines by accessing the theraTRACE® platform.

Melior Discovery is located in Exton, PA. For more information contact:
Andrew Reaume, Ph.D MBA
President and CEO
Melior Discovery
860 Springdale Drive
Exton, PA 19341
(+1) 610-280-0633 ext 239
e-mail: areaume@meliordiscovery.com

View the Archive

Back to top of page